Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Thermo Fisher to buy Brammer Bio for $1.7B, expanding gene therapy offerings and entering the viral vector CDMO space at a moment when capacity is the…
Thermo Fisher buys into gene therapy with $1.7B Brammer deal, joining Catalent (Paragon) in a wave of CDMO consolidation as biopharma scrambles for viral…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Thermo Fisher Scientific agreed to acquire Brammer Bio, a leading viral vector CDMO, for approximately $1.7B in cash. Adds AAV and lentivirus contract manufacturing capacity for gene therapy and gene-modified cell therapy programs. Closed May 1, 2019.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Brammer Bio (this deal) | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2019 deals · Thermo Fisher Scientific Inc. deals · Gene Therapy deals